Tadalafil citrate, also known as Cialis, emerged from cardiovascular research by ICOS Corporation in the early 1990s. The compound, initially named IC351, was later reclassified as a PDE5 inhibitor for erectile dysfunction (ED). Approved by the FDA in 2003, it became known for its extended duration of up to 36 hours, attributed to its β-carboline structure. This feature distinguishes it from other ED drugs, allowing for more spontaneous activity without the need for timed dosing. In 2008, a once-daily dosing option was introduced, further enhancing its appeal.
Coward, R.M. & Carson, C.C., 2008. Tadalafil in the treatment of erectile dysfunction. Therapeutics and Clinical Risk Management.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about Cialis 20 by Unique Pharma, consult with your doctor or healthcare professional.
Coward, R.M. & Carson, C.C., 2008. Tadalafil in the treatment of erectile dysfunction. Therapeutics and Clinical Risk Management.
Coward, R.M. & Carson, C.C., 2008. Tadalafil in the treatment of erectile dysfunction. Therapeutics and Clinical Risk Management.
Coward, R.M. & Carson, C.C., 2008. Tadalafil in the treatment of erectile dysfunction. Therapeutics and Clinical Risk Management.